Angeles Investment Advisors LLC Acquires 367 Shares of Stryker Co. (NYSE:SYK)

Angeles Investment Advisors LLC boosted its holdings in shares of Stryker Co. (NYSE:SYK) by 46.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,149 shares of the medical technology company’s stock after purchasing an additional 367 shares during the quarter. Angeles Investment Advisors LLC’s holdings in Stryker were worth $391,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Burkett Financial Services LLC bought a new stake in shares of Stryker in the fourth quarter valued at approximately $25,000. DSM Capital Partners LLC bought a new stake in Stryker in the 4th quarter valued at $34,000. Central Pacific Bank Trust Division acquired a new stake in Stryker in the 1st quarter worth $39,000. Accent Capital Management LLC bought a new position in shares of Stryker during the 4th quarter worth about $60,000. Finally, Sachetta LLC acquired a new position in shares of Stryker during the fourth quarter valued at about $62,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Up 0.7 %

Shares of SYK opened at $370.25 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.95 and a current ratio of 1.68. The company has a market cap of $141.09 billion, a price-to-earnings ratio of 42.27, a PEG ratio of 2.84 and a beta of 0.91. The stock has a fifty day moving average price of $342.26 and a two-hundred day moving average price of $342.37. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $374.24.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.79 by $0.02. The firm had revenue of $5.42 billion during the quarter, compared to analysts’ expectations of $5.40 billion. Stryker had a net margin of 16.12% and a return on equity of 22.89%. Stryker’s revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.54 EPS. Analysts predict that Stryker Co. will post 12 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be issued a dividend of $0.80 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.20 annualized dividend and a yield of 0.86%. Stryker’s dividend payout ratio is currently 36.53%.

Insider Buying and Selling at Stryker

In other Stryker news, insider Viju Menon sold 600 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the transaction, the insider now directly owns 9,069 shares of the company’s stock, valued at $3,219,495. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Stryker news, Director Ronda E. Stryker sold 190,000 shares of Stryker stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $323.46, for a total transaction of $61,457,400.00. Following the transaction, the director now directly owns 3,316,608 shares in the company, valued at $1,072,790,023.68. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Viju Menon sold 600 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the transaction, the insider now directly owns 9,069 shares of the company’s stock, valued at $3,219,495. The disclosure for this sale can be found here. In the last three months, insiders have sold 210,600 shares of company stock worth $68,330,400. Company insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of recent research reports. Wolfe Research initiated coverage on Stryker in a research report on Tuesday, September 10th. They set an “outperform” rating and a $405.00 target price on the stock. Morgan Stanley boosted their price objective on Stryker from $345.00 to $350.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. The Goldman Sachs Group began coverage on Stryker in a research report on Thursday, May 30th. They issued a “neutral” rating and a $372.00 target price for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $386.00 price target on shares of Stryker in a report on Wednesday, July 31st. Finally, UBS Group raised their price objective on shares of Stryker from $351.00 to $366.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Four equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $378.58.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.